Skip to content
MarketScale
Demo
Creator Hubs›Crown Bioscience
Crown Bioscience logo

News, updates, and expert insights from Crown Bioscience.

Advance translational oncology with Crown Bioscience, a full-service CRO delivering comprehensive preclinical and oncology CRO services worldwide. Follow this channel for the latest from Crown Bioscience: product news, expert perspectives, and updates from the team.

6 episodesVisit website ↗
Channel Brief·Crown Bioscience · 6 episodes
Updated Apr 19, 2025

Cancer resistance is solvable through precision science and new tools

Crown Bioscience argues that drug resistance is not inevitable but predictable and preventable through organoids, biomarkers, AI, and deeper understanding of tumor biology. The channel grounds this in concrete therapies, mutation prevalence, and survival benchmarks.

Crown Bioscience's core argument is that cancer cell adaptation and treatment resistance, while pervasive, can be anticipated and overcome through precision tools and deeper mechanistic insight. The channel supports this by documenting specific resistance challenges (KRAS-driven cancers, immune exhaustion, tumor microenvironment), emerging technologies (organoids, multi-omics, CRISPR, AI), and proven wins (BCR-ABL biomarker raising chronic myeloid leukemia survival from 30-50% to over 90%), showing that targeted innovation consistently unlocks patient-specific solutions.

Drawn from Inside Oncology Drug Development: Overcoming R… and 5 more →

“AI promises a breakthrough: slashing drug development time by nearly half while improving accuracy in identifying promising compounds.”

Exploring Artificial Intelligence in Drug Discovery

By the numbers

90%

five-year survival lift from BCR-ABL biomarker precision medicine

300+

FDA-approved cancer therapies in past two decades

90%

pancreatic cancers harboring KRAS mutations

30-40%

lung and colorectal cancers with KRAS mutations

What the channel argues

DataBCR-ABL biomarker raised chronic myeloid leukemia five-year survival from 30-50% to over 90%.→
InsightOrganoids mimic human biology more closely than 2D models or animal systems, predicting patient-specific drug responses.→
DataOver 300 new cancer therapies approved by FDA in two decades, yet resistance remains the critical challenge.→
DataNearly 90% of pancreatic cancers harbor KRAS mutations; 30-40% of lung and colorectal cancers carry them.→
DataAI reduces drug development timelines by nearly half while improving accuracy in identifying viable compounds.→
InsightCombination therapies and emerging cell-based treatments, including CAR-T and TIL therapies, are expanding immuno-oncology possibilities.→

What you'll learn

•Cancer resistance is not a failure of science but a predictable adaptation problem that precision tools like organoids, biomarkers, and AI can systematically solve.
•The BCR-ABL story in chronic myeloid leukemia proves that identifying the right biomarker can raise five-year survival from 30-50% to over 90%, setting a template for future precision oncology.
•Organoid technology bridges the gap between lab models and human biology, enabling researchers to test drugs on miniature 3D tissues that more accurately predict real patient response than traditional 2D or animal models.
•KRAS mutations drive nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers, but recent FDA approvals of KRAS G12C inhibitors face resistance mechanisms that require combination strategies and deeper mechanistic insight.
•AI is now actively driving oncology innovation, cutting development timelines by nearly half and improving the speed and accuracy with which biotech identifies viable compounds against traditionally intractable targets.

What to do about it

→Invest in and integrate organoid platforms into your drug discovery and development pipeline to predict patient-specific responses and reduce late-stage clinical trial failures.
→Build or partner on multi-omics and AI-driven biomarker discovery programs to identify resistance pathways earlier and inform combination therapy strategies for your pipeline assets.
→Prioritize KRAS and immuno-oncology programs with combination therapy approaches, focusing on preclinical models that capture tumor microenvironment and immune exhaustion to stay ahead of resistance mechanisms.

Who and what shows up

Crown BioScience

Oncology research and drug discovery platform

Leads in AI-driven drug discovery innovation and organoid-based preclinical modeling for oncology programs.

Questions this channel answers

Q

How do scientists predict which cancer therapies will work for individual patients?

Organoid technology, multi-omics, and AI-driven biomarker analysis enable researchers to test drugs on miniature lab-grown 3D tissues and identify patient-specific molecular responses more accurately than traditional models.

Growing the Future of Cancer Research: Inside the Promis… →
Q

Why do cancer cells develop resistance even to cutting-edge therapies?

Cancer cells evolve and adapt to evade therapeutics; resistance pathways can be anticipated and studied using CRISPR, multi-omics, and organoid models to inform next-generation combination strategies.

Inside Oncology Drug Development: Overcoming Resistance … →
Q

What makes the BCR-ABL story in chronic myeloid leukemia so important?

BCR-ABL biomarker identification enabled targeted medicine that raised five-year survival from 30-50% to over 90%, demonstrating the transformative power of precision oncology and serving as a template for future precision medicine approaches.

Evolving Biomarkers: Charting the Future of Precision Me… →
Q

How can immuno-oncology overcome immune cell exhaustion and tumor microenvironment resistance?

Combination therapies integrating CAR-T, TIL therapies, and bispecific antibodies with standard care are being explored to tackle tumor microenvironment challenges and immune exhaustion, with recent FDA approvals expanding the field.

Shaping the Future of Cancer Care Through Immuno-Oncolog… →
Q

How is AI changing the drug discovery timeline?

AI is slashing drug development time by nearly half while improving accuracy in identifying viable compounds, addressing soaring R&D costs and long development cycles as global pharma R&D spending approaches $230 billion by 2026.

Exploring Artificial Intelligence in Drug Discovery →
Topics:Cancer cell resistance and adaptationOrganoid technology and 3D modelsBiomarkers and precision medicineKRAS mutations and targeted inhibitorsImmuno-oncology and combination therapiesAI-driven drug discoveryMulti-omics and personalized treatment
Themes:Resistance is mechanistically solvable, not inevitablePrecision models predict patient-specific outcomes better than broad-brush approachesTechnology convergence (organoids, multi-omics, AI) accelerates insight and timeline compression

Industry context

The global precision oncology market is expanding rapidly, projected to reach $317–329 billion by 2034–2035 from approximately $130–133 billion in 2025–2026, driven by rising cancer prevalence and demand for tailored therapies.

Want a show like this for your brand?

MarketScale produces and distributes branded shows like Crown Bioscience for B2B companies.

Build your show →